Petros Pharmaceuticals, Inc. (PTPI)
USD 0.05
(-3.36%)
USD 0.05
(-3.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.31 Million USD | 35.61% |
| 2022 | 15.71 Million USD | -50.64% |
| 2021 | 31.84 Million USD | -39.21% |
| 2020 | 52.38 Million USD | 4.05% |
| 2019 | 50.34 Million USD | -26.57% |
| 2018 | 68.56 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 15.98 Million USD | -18.53% |
| 2024 Q1 | 19.61 Million USD | -7.96% |
| 2023 Q1 | 15.12 Million USD | -3.79% |
| 2023 FY | 21.31 Million USD | 35.61% |
| 2023 Q3 | 31.85 Million USD | 101.85% |
| 2023 Q2 | 15.78 Million USD | 4.36% |
| 2023 Q4 | 21.31 Million USD | -33.09% |
| 2022 Q3 | 17 Million USD | 1.0% |
| 2022 Q2 | 16.83 Million USD | -16.41% |
| 2022 FY | 15.71 Million USD | -50.64% |
| 2022 Q1 | 20.13 Million USD | -36.76% |
| 2022 Q4 | 15.71 Million USD | -7.54% |
| 2021 Q1 | 45.23 Million USD | -13.66% |
| 2021 FY | 31.84 Million USD | -39.21% |
| 2021 Q4 | 31.84 Million USD | -6.85% |
| 2021 Q3 | 34.18 Million USD | -8.05% |
| 2021 Q2 | 37.17 Million USD | -17.8% |
| 2020 Q4 | 52.38 Million USD | -10.69% |
| 2020 FY | 52.38 Million USD | 4.05% |
| 2020 Q3 | 58.65 Million USD | 9.4% |
| 2020 Q2 | 53.61 Million USD | 0.07% |
| 2020 Q1 | 53.57 Million USD | 6.41% |
| 2019 Q4 | 50.34 Million USD | 0.0% |
| 2019 FY | 50.34 Million USD | -26.57% |
| 2019 Q1 | - USD | 0.0% |
| 2018 FY | 68.56 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 97.751% |
| Embecta Corp. | 2.03 Billion USD | 98.953% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 95.481% |
| Dynavax Technologies Corporation | 375.02 Million USD | 94.316% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 96.774% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 96.973% |
| PainReform Ltd. | 2.69 Million USD | -692.113% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 86.995% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -247.185% |
| SCYNEXIS, Inc. | 55.45 Million USD | 61.559% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -131.779% |
| Cosmos Health Inc. | 30.25 Million USD | 29.541% |
| Journey Medical Corporation | 56.49 Million USD | 62.272% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -247.185% |
| Safety Shot Inc | 3.89 Million USD | -447.676% |
| Alpha Teknova, Inc. | 38.55 Million USD | 44.708% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 84.426% |
| Bright Green Corporation | 6.43 Million USD | -231.088% |
| Procaps Group, S.A. | 462.06 Million USD | 95.387% |
| Theratechnologies Inc. | 98.63 Million USD | 78.39% |
| Harrow Health, Inc. | 241.75 Million USD | 91.183% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -143.442% |
| Biofrontera Inc. | 23.13 Million USD | 7.879% |
| DURECT Corporation | 30.4 Million USD | 29.896% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 95.627% |
| Cronos Group Inc. | 43.73 Million USD | 51.263% |
| OptiNose, Inc. | 194.33 Million USD | 89.031% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 97.392% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 56.0% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -1.61% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 88.247% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -465.085% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 59.411% |
| Radius Health, Inc. | 804.29 Million USD | 97.35% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -54.975% |
| ProPhase Labs, Inc. | 42.54 Million USD | 49.897% |
| Phibro Animal Health Corporation | 725.54 Million USD | 97.062% |
| Procaps Group S.A. | 462.06 Million USD | 95.387% |
| Alvotech | 1.88 Billion USD | 98.868% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -52.017% |
| Viatris Inc. | 27.21 Billion USD | 99.922% |
| Rockwell Medical, Inc. | 30.88 Million USD | 30.977% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 76.415% |
| SIGA Technologies, Inc. | 57.97 Million USD | 63.234% |
| Tilray Brands, Inc. | 892.11 Million USD | 97.611% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 90.302% |
| Shineco, Inc. | 47.6 Million USD | 55.221% |
| PetIQ, Inc. | 645.22 Million USD | 96.696% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -9610.527% |
| Incannex Healthcare Limited | 5.83 Million USD | -265.622% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 97.909% |
| Alimera Sciences, Inc. | 107.35 Million USD | 80.144% |
| Silver Spike Investment Corp. | 3 Million USD | -608.205% |
| Assertio Holdings, Inc. | 148.41 Million USD | 85.638% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1024.27% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -203.384% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -151.053% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 87.706% |
| Hempacco Co., Inc. | 18.82 Million USD | -13.247% |
| Talphera, Inc. | 6.29 Million USD | -238.883% |
| Alvotech | 1.88 Billion USD | 98.868% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 87.65% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 97.448% |
| Currenc Group, Inc. | 177.67 Million USD | 88.003% |
| Kamada Ltd. | 109.96 Million USD | 80.616% |
| Indivior PLC | 1.95 Billion USD | 98.908% |
| Evoke Pharma, Inc. | 9.64 Million USD | -120.933% |
| Flora Growth Corp. | 17.22 Million USD | -23.771% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -151.053% |
| Evolus, Inc. | 209.68 Million USD | 89.834% |
| HUTCHMED (China) Limited | 536.38 Million USD | 96.026% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 97.56% |
| Akanda Corp. | 12.66 Million USD | -68.253% |